Raymond James
A5051102161- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Botulinum Toxin and Related Neurological Disorders
- Genetic Neurodegenerative Diseases
- Parkinson's Disease and Spinal Disorders
- RNA regulation and disease
- Dementia and Cognitive Impairment Research
- Olfactory and Sensory Function Studies
- Customer Service Quality and Loyalty
- Conducting polymers and applications
- Gout, Hyperuricemia, Uric Acid
- Urinary Bladder and Prostate Research
- Cardiovascular Issues in Pregnancy
- Yeasts and Rust Fungi Studies
- Avian ecology and behavior
- Adenosine and Purinergic Signaling
- Hepatitis B Virus Studies
- Economic and Environmental Valuation
- Alzheimer's disease research and treatments
- Metabolism and Genetic Disorders
- Forest Insect Ecology and Management
- Neurological diseases and metabolism
- Plant Pathogens and Resistance
- Bird parasitology and diseases
- Voice and Speech Disorders
The Huntington Library, Art Museum, and Botanical Gardens
2022
Boston Medical Center
2016-2021
Boston University
2012-2017
University Medical Center
2017
Thomas Jefferson University
1996
St George's Hospital
1991
St George's, University of London
1991
<h3>Importance</h3> Deutetrabenazine is a novel molecule containing deuterium, which attenuates CYP2D6 metabolism and increases active metabolite half-lives may therefore lead to stable systemic exposure while preserving key pharmacological activity. <h3>Objective</h3> To evaluate efficacy safety of deutetrabenazine treatment control chorea associated with Huntington disease. <h3>Design, Setting, Participants</h3> Ninety ambulatory adults diagnosed manifest disease baseline total maximal...
IMPORTANCE Convergent biological, epidemiological, and clinical data identified urate elevation as a candidate strategy for slowing disability progression in Parkinson disease (PD).OBJECTIVE To determine the safety, tolerability, urate-elevating capability of precursor inosine early PD to assess its suitability potential design features disease-modification trial. DESIGN, SETTING, AND PARTICIPANTSThe Safety Urate Elevation (SURE-PD) study, randomized, double-blind, placebo-controlled,...
Urate elevation, despite associations with crystallopathic, cardiovascular, and metabolic disorders, has been pursued as a potential disease-modifying strategy for Parkinson disease (PD) based on convergent biological, epidemiological, clinical data.To determine whether sustained urate-elevating treatment the urate precursor inosine slows early PD progression.Randomized, double-blind, placebo-controlled, phase 3 trial of oral in PD. A total 587 individuals consented, 298 not yet requiring...
Abstract To test the association between impaired olfaction and other prodromal features of PD in Parkinson At‐Risk Syndrome Study. The onset olfactory dysfunction typically precedes motor features, suggesting that testing could be used as a screening test. A combined strategy uses nonmotor along with testing, may more efficient than hyposmia alone for detecting risk PD. Individuals no neurological diagnosis completed mail survey, including 40‐item University Pennsylvania Smell...
To analyze longitudinal levels of CSF biomarkers in drug-naive patients with Parkinson disease (PD) and healthy controls (HC), examine the extent to which these biomarker changes relate clinical measures PD, identify what may influence them.CSF α-synuclein (α-syn), total phosphorylated tau (t- p-tau), β-amyloid 1-42 (Aβ42) were measured at baseline 6 12 months 173 PD 112 matched HC international multicenter Parkinson's Progression Marker Initiative. Baseline demographic variables,...
It is widely cited that dementia occurs in up to 80% of patients with Parkinson disease (PD), but studies reporting such high rates were published over two decades ago, had relatively small samples, and other limitations. We aimed determine long-term risk PD using data from large, ongoing, prospective, observational studies.
Among LRRK2-associated parkinsonism cases with nigral degeneration, over two-thirds demonstrate evidence of pathologic alpha-synuclein, but many do not. Understanding the clinical phenotype and underlying biology in such individuals is critical for therapeutic development. Our objective was to compare biomarker features, rate progression 4 years follow-up, among without vivo alpha-synuclein aggregates. Data were from Parkinson's Progression Markers Initiative, a multicentre prospective...
Deutetrabenazine is approved in the USA, China, Australia, Israel, Brazil, and South Korea for treatment of chorea associated with Huntington disease. We aimed to evaluate long-term safety tolerability deutetrabenazine This open-label, single-arm, multi-center study included patients who completed a double-blind (Rollover) converted overnight from stable tetrabenazine dose (Switch). Exposure-adjusted incidence rates (adverse events per person-year) were calculated. Efficacy was analyzed...
Objective: To assess the prevalence of Parkinson’s disease (PD) among African- Americans compared to non-Hispanic Whites in a tertiary urban Movement Disorders center. Background: Contributing factors based on race may improve health disparities United States. According largest study analyzing and incidence PD Medicare beneficiaries, ratio African-Americans (AA) Caucasians general population is 9%, while AA approximately 5%. Methods: We performed retrospective analysis African-American...